Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00440388

Public ClinicalTrials.gov record NCT00440388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT00440388
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ascenta Therapeutics
Industry
Enrollment
23 participants

Conditions and interventions

Interventions

  • AT-101 Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2006
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008
Last update posted
Aug 26, 2010

2006 – 2008

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35296
Hematology Oncology Associates Phoenix Arizona
Rocky Mountain Cancer Center-Aurora Aurora Colorado
Florida Cancer Institute Hudson Florida 34667
Florida Cancer Institute New Port Richey Florida 34655
Cancer Care & Hematology Specialists of Chicagoland Arlington Heights Illinois
Central Indiana Cancer Centers Fishers Indiana
University of Michigan Cancer Center Ann Arbor Michigan 48109
Minnesota Oncology Hematology, P.A. Minneapolis Minnesota
Missouri Cancer Associates Columbia Missouri
Comprehensive Cancer Centers of Nevada Henderson Nevada
Hematology/Oncology Associates Albuquerque New Mexico 87106
New York Oncology Hematology, P.C. Albany New York
Duke University Medical Center Durham North Carolina 27707
Northwest Cancer Specialists Portland Oregon
The Jones Clinic Germantown Tennessee 38138
Texas Oncology, P.A. Bedford Texas
Texas Cancer Center at Medical City Dallas Texas
Texas Oncology, P.A. Fort Worth Texas
Allison Cancer Center Midland Texas
HOAST - New Braunfels New Braunfels Texas
West Texas Cancer Center Odessa Texas
Hematology Oncology Physicians of Texas Richardson Texas 75080
Tyler Cancer Center Tyler Texas
Virginia Oncology Associates Chesapeake Virginia
Oncology and Hematology Associates of SW Virginia, Inc. Salem Virginia 24153
Cancer Care Northwest Spokane Washington 99202
St. Mary's Medical Center Huntington West Virginia 25701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00440388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 26, 2010 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00440388 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →